General Information and Variability Data of DT
DT ID DTD0003
Gene Name ABCB1
Protein Name P-glycoprotein 1
Synonyms ABC20; ABCB1; ATP-binding cassette sub-family B member 1; CD243; CLCS; GP170; MDR1; P-GP; PGY1
Gene ID
5243
UniProt ID
P08183
TCDB ID
3.A.1.201.1
DT Family ATP-Binding Cassette (ABC) Superfamily
Multidrug Resistance Exporter (MDR) Family (ABCB)
Tissue Specificity Intestinal enterocyte, kidney proximal tubule, hepatocyte (canalicular), brain endothelia, high expression on the surface of many transformed and tumor cell lines
Function This energy-dependent efflux pump transporter responsible for decreased drug accumulation in multidrug-resistant cells.
Disease(s) Chronic obstructive pulmonary disease [ICD-11: CA22]
Colorectal cancer [ICD-11: 2B91]
Fibromyalgia [ICD-11: MG30.01]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Malaria [ICD-11: 1F40]
Moderate to severe rheumatoid arthritis [ICD-11: FA20]
Organ transplant rejection [ICD-11: NE84]
Overactive bladder disorder [ICD-11: GC50.0]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Abacavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [1]
Acebutolol Drug Info Ventricular premature beats [ICD-11: BC70] Approved [2]
Acrivastine Drug Info Seasonal allergic rhinitis [ICD-11: CA08.01] Approved [3]
Actinomycin D Drug Info Rhabdomyosarcoma [ICD-11: 2B55] Approved [4]
Afatinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [5]
Ajmaline Drug Info Atrial fibrillation [ICD-11: BC81.3] Approved [6]
Albendazole Drug Info Parasitic worm infestations [ICD-11: 1F90] Approved [7]
Aldosterone Drug Info High blood pressure [ICD-11: BA00] Approved [8]
Aliskiren fumarate Drug Info High blood pressure [ICD-11: BA00] Approved [9]
Ambrisentan Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [10]
Amiodarone Drug Info Tachyarrhythmias [ICD-11: BC71, BC81] Approved [4]
Amisulpride Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Amitriptyline Drug Info Major depressive disorder [ICD-11: 6A70.3] Approved [12]
Amoxicillin Drug Info Streptococcal pharyngitis [ICD-11: 1B51] Approved [2]
Amphotericin B Drug Info Fungal infections [ICD-11: 1F20-1F2Z] Approved [13]
Amprenavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [4]
Apixaban Drug Info Thrombosis [ICD-11: BD71.4, BD72] Approved [14]
Apremilast Drug Info Plaque psoriasis [ICD-11: EA90.0] Approved [15]
Aprepitant Drug Info Nausea and vomiting [ICD-11: MD90] Approved [16]
Arsenic trioxide Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [17]
Aspirin Drug Info Pain [ICD-11: MG30-MG7Z] Approved [12]
Atenolol Drug Info High blood pressure [ICD-11: BA00] Approved [18]
Atomoxetine Drug Info Attention deficit hyperactivity disorder [ICD-11: 6A05] Approved [16]
Atorvastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [15]
Axitinib Drug Info Advanced renal cell carcinoma [ICD-11: 2C90] Approved [19]
Azasetron Drug Info Nausea and vomiting [ICD-11: MD90] Approved [2]
Azathioprine Drug Info Organ transplant rejection [ICD-11: NE84] Approved [12]
Azithromycin Drug Info Traveler's diarrhea [ICD-11: ME05.1] Approved [20]
Baloxavir marboxil Drug Info Influenza A infection [ICD-11: 1.00E+31] Approved [21]
Baricitinib Drug Info Psoriasis [ICD-11: EA90] Approved [22]
Beclomethasone Drug Info Perennial and seasonal allergic rhinitis [ICD-11: CA08.0] Approved [23]
Bepridil Drug Info Chronic stable angina [ICD-11: BA40] Approved [4]
Beta-Acetyldigoxin Drug Info Cardiovascular disorder [ICD-11: BA00-BE2Z] Approved [24]
Beta-Carotene Drug Info Vitamin deficiency [ICD-11: 5B55-5B7Z] Approved [13]
Betamethasone Drug Info Asthma [ICD-11: CA23] Approved [25]
Betrixaban Drug Info Venous thromboembolism [ICD-11: BD72] Approved [26]
Bicalutamide Drug Info Prostate cancer [ICD-11: 2C82] Approved [27]
Binimetinib Drug Info Melanoma [ICD-11: 2C30] Approved [28]
Boceprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [29]
Bortezomib Drug Info Mantle cell lymphoma [ICD-11: 2A85.5] Approved [30]
Bosutinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [31]
Brilinta Drug Info Thrombosis [ICD-11: BD71.4, BD72] Approved [32]
Bromocriptine Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [16]
Bupropion Drug Info Smoking cessation [ICD-11: 6C4A.2] Approved [33]
Cabergoline Drug Info Hyperprolactinemia [ICD-11: 5A60.1] Approved [34]
Canagliflozin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [35]
Cannabidiol Drug Info Dravet syndrome [ICD-11: 8A61.11] Approved [32]
Carfilzomib Drug Info Multiple myeloma [ICD-11: 2A83] Approved [36]
Carvedilol Drug Info Congestive heart failure [ICD-11: BD10] Approved [15]
Cefoperazone Drug Info Pseudomonas bacterial infections [ICD-11: 1B92] Approved [4]
Cefotetan Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [2]
Ceftriaxone Drug Info Pneumonia [ICD-11: CA40] Approved [4]
Celiprolol Drug Info High blood pressure [ICD-11: BA00] Approved [37]
Cepharanthine Drug Info Thrombocytopenia [ICD-11: 3B64] Approved [38]
Ceritinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [39]
Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [40]
Cetirizine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [41]
Chlorambucil Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Approved [4]
Chloramphenicol Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [42]
Chloroquine Drug Info Malaria [ICD-11: 1F40] Approved [16]
Chlorpromazine Drug Info Schizophrenia [ICD-11: 6A20] Approved [4]
Ciclesonide Drug Info Asthma [ICD-11: CA23] Approved [23]
Cimetidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [4]
Cinchonidine Drug Info Malaria [ICD-11: 1F40] Approved [2]
Cisplatin Drug Info Testicular cancer [ICD-11: 2C80] Approved [4]
Citalopram Drug Info Depression [ICD-11: 6A8Z] Approved [43]
Clarithromycin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Clobazam Drug Info Epilepsy [ICD-11: 8A6Z] Approved [15]
Clofazimine Drug Info Leprosy [ICD-11: 1B20] Approved [44]
Clomifene Drug Info Female infertility [ICD-11: GA31] Approved [45]
Clomiphene citrate Drug Info Female infertility due to anovulation [ICD-11: GA31] Approved [45]
Clomipramine Drug Info Depression [ICD-11: 6A8Z] Approved [16]
Clonidine Drug Info High blood pressure [ICD-11: BA00] Approved [12]
Clopidogrel Drug Info Thrombosis [ICD-11: BD71.4, BD72] Approved [46]
Clozapine Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Colchicine Drug Info Acute gouty arthritis [ICD-11: FA25] Approved [47]
Cortisone Drug Info Atopic dermatitis [ICD-11: EA80] Approved [25]
Crizotinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [48]
Cyclosporine Drug Info Xerophthalmia [ICD-11: 5B55.Y] Approved [49]
Cytarabine Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [4]
Dabigatran Drug Info Stroke in atrial fibrillation [ICD-11: 8B11.20] Approved [50]
Dabrafenib Drug Info Melanoma [ICD-11: 2C30] Approved [51]
Daclatasvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [50]
Dactinomycin Drug Info Cancer [ICD-11: 2A00-2F9Z] Approved [52]
Darunavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [53]
Dasatinib Drug Info Multiple myeloma [ICD-11: 2A83] Approved [54]
Daunorubicin Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [4]
Debrisoquine Drug Info Hypertension [ICD-11: BA00] Approved [55]
Deflazacort Drug Info Duchenne muscular dystrophy [ICD-11: 8C70.1] Approved [32]
Delavirdine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [1]
Desipramine Drug Info Depression [ICD-11: 6A8Z] Approved [56]
Desloratadine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [57]
Dexamethasone Drug Info Rheumatoid arthritis [ICD-11: FA20] Approved [58]
Diazepam Drug Info Anxiety [ICD-11: MB24.3] Approved [59]
Dicloxacillin Drug Info Susceptible gram-positive bacteria infections [ICD-11: 1A00-1H0Z] Approved [60]
Diethylstilbestrol Drug Info Gonorrheal vaginitis [ICD-11: GA02.1] Approved [45]
Digitoxin Drug Info Heart failure [ICD-11: BD1Z] Approved [61]
Digoxin Drug Info Arrhythmias [ICD-11: BC60-BC9Z] Approved [62]
Dihydroergocristine Drug Info Alcohol use disorders [ICD-11: 6C40] Approved [63]
Diltiazem Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Dipyridamole Drug Info High blood pressure [ICD-11: BA00] Approved [16]
Docetaxel Drug Info Lung cancer [ICD-11: 2C25] Approved [64]
Dolutegravir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Domperidone Drug Info Gastrointestinal problems [ICD-11: DE2Z] Approved [11]
Doxorubicin Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [65]
Doxorubicin Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [66]
Doxycycline Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Edoxaban Drug Info Atrial fibrillation [ICD-11: BC81.3] Approved [67]
Efavirenz Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [2]
Eletriptan Drug Info Migraine Headaches [ICD-11: 8A80] Approved [16]
Eliglustat tartrate Drug Info Metabolic disorders [ICD-11: 5C50] Approved [32]
Emetine Drug Info Hepatitis virus infection [ICD-11: 1E5Z] Approved [52]
Empagliflozin Drug Info Type 1 diabetes [ICD-11: 5A10] Approved [32]
Epinastine Drug Info Cardiovascular disorder [ICD-11: BA00-BE2Z] Approved [68]
Epirubicin Drug Info Node-positive breast cancer [ICD-11: 2C60-2C6Z] Approved [4]
Ergotamine Drug Info Headache [ICD-11: MB6Y] Approved [16]
Erlotinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [69]
Erythromycin Drug Info Pelvic inflammatory disease [ICD-11: GA05] Approved [70]
Eslicarbazepine acetate Drug Info Partial seizures [ICD-11: 8A68.0] Approved [71]
Estradiol Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [45]
Estriol Drug Info Menopausal symptoms [ICD-11: MF32] Approved [72]
Estrone Drug Info Postmenopausal disorder [ICD-11: GA30.Z] Approved [72]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [40]
Ethinyl estradiol Drug Info Female hypogonadism [ICD-11: 5A61.0] Approved [72]
Etoposide Drug Info Testicular cancer [ICD-11: 2C80] Approved [73]
Everolimus Drug Info Renal cell carcinoma [ICD-11: 2C90] Approved [74]
Ezetimibe Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [75]
Famciclovir Drug Info Viral infections [ICD-11: 1D90-1D9Z] Approved [3]
Felodipine Drug Info High blood pressure [ICD-11: BA00] Approved [76]
Fentanyl Drug Info Analgesia [ICD-11: MB40.8] Approved [4]
Fesoterodine fumarate Drug Info Overactive bladder disorder [ICD-11: GC50.0] Approved [77]
Fexofenadine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [78]
Fluorouracil Drug Info Stomach cancer [ICD-11: 2B72] Approved [4]
Fluoxetine Drug Info Depression [ICD-11: 6A8Z] Approved [79]
Flupentixol Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Fluphenazine Drug Info Psychotic disorders [ICD-11: 6A2Z] Approved [11]
Fluticasone propionate Drug Info Asthma [ICD-11: CA23] Approved [23]
Fluvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [56]
Fluvoxamine Drug Info Obsessive compulsive disorder [ICD-11: 6B20] Approved [11]
Folic acid Drug Info Vitamin deficiency [ICD-11: 5B55-5B7Z] Approved [80]
Fosamprenavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Gatifloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [81]
Gefitinib Drug Info Urethral cancer [ICD-11: 2F78] Approved [82]
Gemcitabine Drug Info Cholangiocarcinoma [ICD-11: 2C12.10] Approved [83]
Gilteritinib Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [32]
Glutathione Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [84]
Gramicidin D Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Grepafloxacin Drug Info Chronic bronchitis [ICD-11: CA20.1] Approved [4]
Guanabenz Drug Info Hypertension [ICD-11: BA00] Approved [56]
Haloperidol Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Hydrocortisone Drug Info Inflammatory disease [ICD-11: 9B72] Approved [23]
Hydroxyurea Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [4]
Ibrutinib Drug Info Waldenstrom's macroglobulinemia [ICD-11: 2A85.4] Approved [85]
Idarubicin Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [86]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [87]
Imipramine Drug Info Major depressive disorder [ICD-11: 6A70.3] Approved [12]
Indacaterol Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Approved [32]
Indinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [88]
Indomethacin Drug Info Moderate to severe rheumatoid arthritis [ICD-11: FA20] Approved [89]
Ingenol-3-angelate Drug Info Actinic keratosis [ICD-11: EK90.0] Approved [90]
Irinotecan Drug Info Colorectal cancer [ICD-11: 2B91] Approved [91]
Itraconazole Drug Info Fungal infections [ICD-11: 1F20-1F2Z] Approved [4]
Ivacaftor Drug Info Cystic fibrosis [ICD-11: CA25] Approved [92]
Ivermectin Drug Info Strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved [93]
Ivosidenib Drug Info Cholangiocarcinoma [ICD-11: 2C12.10] Approved [94]
Ixabepilone Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [95]
Ketoconazole Drug Info Fungal infections [ICD-11: 1F20-1F2Z] Approved [4]
L-tryptophan Drug Info Depression [ICD-11: 6A8Z] Approved [96]
Labetalol Drug Info Hypertension [ICD-11: BA00] Approved [2]
Lamotrigine Drug Info Epilepsy [ICD-11: 8A6Z] Approved [97]
Lansoprazole Drug Info Peptic ulcer [ICD-11: DA61] Approved [56]
Lapatinib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [15]
Ledipasvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [15]
Lenalidomide Drug Info Anaemia [ICD-11: 3A9Z] Approved [98]
Lenvatinib Drug Info Ovarian cancer [ICD-11: 2C73] Approved [99]
Levetiracetam Drug Info Epilepsy [ICD-11: 8A6Z] Approved [100]
Levodopa Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [2]
Levofloxacin Drug Info Gram-positive & negative bacteria infections [ICD-11: 1A00-1H0Z] Approved [4]
Levomepromazine Drug Info Psychosis [ICD-11: 6A2Y] Approved [11]
Levomilnacipran Drug Info Fibromyalgia [ICD-11: MG30.01] Approved [101]
Lidocaine Drug Info Ventricular tachycardia [ICD-11: BC71.0] Approved [4]
Linagliptin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [15]
Loperamide Drug Info Acute diarrhea [ICD-11: ME05.1] Approved [102]
Lopinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [103]
Loratadine Drug Info Allergy [ICD-11: 4A8Z] Approved [57]
Losartan Drug Info High blood pressure [ICD-11: BA00] Approved [104]
Lovastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [4]
Lovastatin acid Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [2]
Maraviroc Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Mefloquine Drug Info Malaria [ICD-11: 1F40] Approved [105]
Melphalan Drug Info Multiple myeloma [ICD-11: 2A83] Approved [106]
Meperidine Drug Info Moderate to severe pain [ICD-11: MG30-MG3Z] Approved [107]
Mequitazine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [3]
Methadone Drug Info Pain [ICD-11: MG30-MG7Z] Approved [108]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [4]
Methylprednisolone Drug Info Systemic lupus erythematosus [ICD-11: 4A40.0] Approved [109]
Methysergide Drug Info Migraine [ICD-11: 8A80] Approved [3]
Midazolam Drug Info Seizure [ICD-11: 8A68] Approved [56]
Midostaurin Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [2]
Mitomycin Drug Info Anxiety [ICD-11: MB24.3] Approved [110]
Mitoxantrone Drug Info Metastatic breast cancer [ICD-11: 2C6Y] Approved [4]
Morphine Drug Info Chronic pain [ICD-11: MG30] Approved [111]
Moxidectin Drug Info Onchocerciasis [ICD-11: 1F6A] Approved [112]
Mycophenolate mofetil Drug Info Pemphigus vulgaris [ICD-11: EB40.0] Approved [113]
Nadolol Drug Info High blood pressure [ICD-11: BA00] Approved [15]
Nalbuphine Drug Info Pain [ICD-11: MG30-MG7Z] Approved [3]
Naloxegol Drug Info Opioid-induced constipation [ICD-11: ME05.0] Approved [15]
Nelfinavir Drug Info Sars coronavirus infections [ICD-11: 1D92] Approved [114]
Neostigmine Drug Info Myasthenia gravis [ICD-11: 8C60] Approved [16]
Nevirapine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [2]
Nicardipine Drug Info High blood pressure [ICD-11: BA00] Approved [58]
Nifedipine Drug Info Angina [ICD-11: BA40] Approved [4]
Nilotinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [32]
Nimodipine Drug Info Cerebral vasospasm [ICD-11: BA85.Z] Approved [2]
Nintedanib Drug Info Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved [115]
Nisoldipine Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Nitrendipine Drug Info High blood pressure [ICD-11: BA00] Approved [4]
Nizatidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [116]
Norfloxacin Drug Info Urinary tract infections [ICD-11: GC08] Approved [2]
Olanzapine Drug Info Bipolar disorder [ICD-11: 6A60-6A61] Approved [11]
Olaparib Drug Info Ovarian cancer [ICD-11: 2C73] Approved [117]
Olmesartan medoxomil Drug Info High blood pressure [ICD-11: BA00] Approved [32]
Olopatadine Drug Info Itching of the eye due to allergic conjunctivitis [ICD-11: 9A60.02] Approved [2]
Omadacycline Drug Info Community-acquired bacterial pneumonia [ICD-11: CA40.0Z] Approved [118]
Omeprazole Drug Info Gastroesophageal reflux disease [ICD-11: DA22] Approved [56]
Ondansetron Drug Info Nausea and vomiting associated with chemotherapy [ICD-11: MD90] Approved [105]
Oseltamivir Drug Info Influenza virus [ICD-11: 1E30-1E32] Approved [119]
Oxcarbazepine Drug Info Epilepsy [ICD-11: 8A6Z] Approved [120]
Paclitaxel Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [121]
Palbociclib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [122]
Paliperidone Drug Info Schizophrenia [ICD-11: 6A20] Approved [123]
Panobinostat Drug Info Multiple myeloma [ICD-11: 2A83] Approved [124]
Pantoprazole Drug Info Gastroesophageal reflux disease [ICD-11: DA22] Approved [56]
Paroxetine Drug Info Depression [ICD-11: 6A8Z] Approved [16]
Pazopanib hydrochloride Drug Info Renal cell carcinoma [ICD-11: 2C90] Approved [125]
Pemirolast Drug Info Itching of the eye due to allergic conjunctivitis [ICD-11: 9A60.02] Approved [2]
Pentazocine Drug Info Moderate to severe pain [ICD-11: MG30-MG3Z] Approved [4]
Perazine Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Perphenazine Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Phenobarbital Drug Info Seizure [ICD-11: 8A68] Approved [120]
Phenprocoumon Drug Info Pulmonary embolism [ICD-11: BB00] Approved [126]
Phenytoin Drug Info Seizures following neurosurgery [ICD-11: 8A6Z] Approved [120]
Pibrentasvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [15]
Pimozide Drug Info Schizophrenia [ICD-11: 6A20] Approved [2]
Pirarubicin Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [2]
Pirenzepine Drug Info Peptic ulcer [ICD-11: DA61] Approved [3]
Pomalidomide Drug Info Systemic sclerosis [ICD-11: 4A42.0] Approved [127]
Ponatinib Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [128]
Posaconazole Drug Info Aspergillosis [ICD-11: 1F20] Approved [32]
Pravastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [15]
Prazosin Drug Info Severe congestive heart failure [ICD-11: BD10] Approved [129]
Prednisolone Drug Info Adrenocortical insufficiency [ICD-11: 5A74] Approved [130]
Prednisone Drug Info Inflammatory disease [ICD-11: 9B72] Approved [25]
Progesterone Drug Info Premature labour [ICD-11: JB00] Approved [59]
Propafenone Drug Info Tachyarrhythmias [ICD-11: BC71, BC81] Approved [4]
Propranolol Drug Info Migraine [ICD-11: 8A80] Approved [15]
Protriptyline Drug Info Depression [ICD-11: 6A8Z] Approved [3]
Prucalopride Drug Info Chronic idiopathic constipation [ICD-11: ME05.0] Approved [131]
Quercetin Drug Info Coronary artery disease [ICD-11: BA6Z] Approved [132]
Quetiapine Drug Info Schizophrenia [ICD-11: 6A20] Approved [11]
Quinine Drug Info Malaria [ICD-11: 1F40] Approved [4]
Raloxifene Drug Info Osteoporosis [ICD-11: FB83.1] Approved [133]
Ramosetron Drug Info Irritable bowel syndrome [ICD-11: DD91.0] Approved [134]
Ranitidine Drug Info Peptic ulcer [ICD-11: DA61] Approved [4]
Ranolazine Drug Info Chronic angina [ICD-11: BA40] Approved [135]
Regorafenib Drug Info Metastatic colorectal cancer [ICD-11: 2B91] Approved [136]
Reserpine Drug Info High blood pressure [ICD-11: BA00] Approved [16]
Rifampicin Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [4]
Rifaximin Drug Info Traveler's diarrhea [ICD-11: ME05.1] Approved [137]
Riociguat Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [138]
Risperidone Drug Info Schizophrenia [ICD-11: 6A20] Approved [139]
Ritonavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [140]
Rivaroxaban Drug Info Prophylaxis of deep vein thrombosis [ICD-11: BD71] Approved [141]
Romidepsin Drug Info Cutaneous T-cell lymphoma [ICD-11: 2B0Z] Approved [142]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [143]
S-licarbazepine Drug Info Partial seizures [ICD-11: 8A68.0] Approved [71]
Saphris Drug Info Schizophrenia [ICD-11: 6A20] Approved [2]
Saquinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [144]
Saxagliptin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [15]
Sertraline Drug Info Depression [ICD-11: 6A8Z] Approved [16]
Silodosin Drug Info Benign prostatic hyperplasia [ICD-11: GA90] Approved [145]
Simeprevir Drug Info Chronic hepatitis C infection [ICD-11: 1E51.1] Approved [32]
Simvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [4]
Sirolimus Drug Info Organ transplant rejection [ICD-11: NE84] Approved [146]
Sitagliptin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [15]
Sofosbuvir Drug Info Chronic hepatitis C infection [ICD-11: 1E51.1] Approved [147]
Sorafenib Drug Info Pancreatic cancer [ICD-11: 2C10] Approved [148]
Sparfloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [4]
Spiperone Drug Info Schizophrenia [ICD-11: 6A20] Approved [2]
Sumatriptan Drug Info Migraine Headaches [ICD-11: 8A80] Approved [149]
Sunitinib Drug Info Imatinib-resistant gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [150]
Sunitinib malate Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [151]
Tacrine Drug Info Alzheimer disease [ICD-11: 8A20] Approved [152]
Tacrolimus Drug Info Organ transplant rejection [ICD-11: NE84] Approved [4]
Tadalafil Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [153]
Talazoparib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [154]
Tamoxifen Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [4]
Telaprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Approved [29]
Telithromycin Drug Info Community acquired pneumonia [ICD-11: CA40] Approved [155]
Temsirolimus Drug Info Renal cell carcinoma [ICD-11: 2C90] Approved [156]
Teniposide Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [4]
Tenofovir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [32]
Tenoxicam Drug Info Rheumatoid arthritis [ICD-11: FA20] Approved [2]
Testosterone Drug Info Osteoporosis [ICD-11: FB83.1] Approved [56]
Tetracycline Drug Info Gram-positive & negative bacteria infections [ICD-11: 1A00-1H0Z] Approved [4]
Thiamphenicol Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [42]
Thioridazine Drug Info Schizophrenia [ICD-11: 6A20] Approved [16]
Timolol Drug Info High blood pressure [ICD-11: BA00] Approved [37]
Tolvaptan Drug Info Hypervolaemic hyponatraemia [ICD-11: 5C72] Approved [157]
Topiramate Drug Info Partial seizures [ICD-11: 8A68.0] Approved [158]
Topotecan Drug Info Ovarian cancer [ICD-11: 2C73] Approved [159]
Toremifene Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [45]
Tramadol Drug Info Pain [ICD-11: MG30-MG7Z] Approved [160]
Tretinoin Drug Info Acne vulgaris [ICD-11: ED80] Approved [13]
Trifluoperazine Drug Info Generalized non-psychotic anxiety [ICD-11: 6B00] Approved [4]
Triflupromazine Drug Info Psychosis [ICD-11: 6A2Y] Approved [2]
Trimethoprim Drug Info Urinary tract infections [ICD-11: GC08] Approved [16]
Triprolidine Drug Info Allergic rhinitis [ICD-11: CA08.0] Approved [161]
Trospium chloride Drug Info Overactive bladder [ICD-11: GC50.0] Approved [162]
Vecuronium Drug Info Spasms [ICD-11: MB47.3] Approved [105]
Vemurafenib Drug Info Thyroid cancer [ICD-11: 2D10] Approved [163]
Venetoclax Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Approved [164]
Verapamil Drug Info High blood pressure [ICD-11: BA00] Approved [165]
Vildagliptin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [166]
Vinblastine Drug Info Testicular cancer [ICD-11: 2C80] Approved [167]
Vincristine Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [168]
Vindesine Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [2]
Vinorelbine Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [169]
Zidovudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [1]
Ziprasidone Drug Info Schizophrenia [ICD-11: 6A20] Approved [16]
Zolmitriptan Drug Info Migraine without aura [ICD-11: 8A80.0] Approved [16]
Clinical Trial Drug(s) Transported by This DT Beclomethasone dipropionate Drug Info Allergic rhinitis [ICD-11: CA08.0] Phase 4 [23]
Berberine Drug Info Diabetes [ICD-11: 5A10-5A14] Phase 4 [170]
Biotin Drug Info Biotin ingestion [ICD-11: 5B5G] Phase 4 [171]
Ebastine Drug Info Irritable bowel syndrome [ICD-11: DD91.0] Phase 4 [2]
Guanfacine Drug Info Primary liver cancer [ICD-11: 2C12.0] Phase 4 [172]
Ombitasvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 4 [15]
Tenofovir disoproxil Drug Info Chronic hepatitis B infection [ICD-11: 1E51.0] Phase 4 [2]
4-Hydroxytamoxifen Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Phase 3 [45]
Asimadoline Drug Info Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 [4]
Asunaprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 3 [32]
Belotecan Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 3 [2]
Corticosterone Drug Info Coxarthrosis [ICD-11: FA00] Phase 3 [45]
Crocin Drug Info Knee osteoarthritis [ICD-11: FA01] Phase 3 [13]
Dasabuvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 3 [15]
Morphine-6-glucuronide Drug Info Postoperative Pain [ICD-11: MG31.2] Phase 3 [2]
Pazufloxacin Drug Info Bacterial conjunctivitis [ICD-11: 9A60] Phase 3 [173]
Relugolix Drug Info Endometriosis [ICD-11: GA10] Phase 3 [32]
Simvastatin acid Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 [174]
Tenofovir alafenamide Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Phase 3 [175]
Vibegron Drug Info Overactive bladder disorder [ICD-11: GC50.0] Phase 3 [32]
Sitafloxacin Drug Info Escherichia Coli Infections [ICD-11: 1A03] Phase 2/3 [2]
(Z)-endoxifen Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Phase 2 [176]
ABT-263 Drug Info Myelofibrosis [ICD-11: 2A20.2] Phase 2 [177]
Bisantrene Drug Info Acute myelogenous leukemia [ICD-11: 2B33.1] Phase 2 [4]
Cholesterol Drug Info Cone-Rod dystrophy [ICD-11: 9B70] Phase 2 [178]
CP-122721 Drug Info Major depressive disorder [ICD-11: 6A70.3] Phase 2 [179]
Curcumin Drug Info Cancer [ICD-11: 2A00-2F9Z] Phase 2 [4]
Dihydrotestosterone Drug Info Female hypogonadism [ICD-11: 5A61.0] Phase 2 [180]
Dolastatin 10 Drug Info Leukemia [ICD-11: 2A60-2B33] Phase 2 [181]
Flavonoids Drug Info Colorectal cancer [ICD-11: 2B91] Phase 2 [4]
Fucoxanthin Drug Info Metabolic syndrome [ICD-11: 5A40-5A4Z] Phase 2 [13]
Gallopamil Drug Info Asthma [ICD-11: CA23] Phase 2 [2]
Gepirone Drug Info Cocaine related disorders [ICD-11: 6C45] Phase 2 [2]
Glecaprevir Drug Info Chronic hepatitis C infection [ICD-11: 1E51.1] Phase 2 [15]
Norverapamil Drug Info Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 [182]
NSC325663 Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 [66]
Paritaprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 2 [15]
Roscovitine Drug Info Cystic fibrosis [ICD-11: CA25] Phase 2 [183]
Staurosporine Drug Info Discovery agent [ICD-11: N.A.] Phase 2 [2]
Genz 644282 Drug Info Solid tumours [ICD-11: 2D4Z] Phase 1 [184]
Naringenin Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 1 [132]
Norbuprenorphine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Phase 1 [185]
Prostaglandin A2 Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Phase 1 [186]
Sphingosine-1-phosphate Drug Info Acne vulgaris [ICD-11: ED80] Phase 1 [187]
Substance P Drug Info Type 1 diabetes [ICD-11: 5A10] Phase 1 [188]
Talinolol Drug Info Gastrointestinal motility disorder [ICD-11: DE2Z] Phase 1 [189]
Velpatasvir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 1 [15]
Voxilaprevir Drug Info Hepatitis C virus infection [ICD-11: 1E50.2, 1E51.1] Phase 1 [15]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Alprenolol Drug Info High blood pressure [ICD-11: BA00] Withdrawn [56]
Astemizole Drug Info Allergic rhinitis [ICD-11: CA08.0] Withdrawn [16]
Isoxicam Drug Info Osteoarthritis [ICD-11: FA0Z] Withdrawn [2]
Melagatran Drug Info Atrial fibrillation [ICD-11: BC81.3] Withdrawn [2]
Mibefradil Drug Info Ovarian cancer [ICD-11: 2C73] Withdrawn [2]
Mithramycin Drug Info Cancer [ICD-11: 2A00-2F9Z] Withdrawn [2]
Roxithromycin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Withdrawn [155]
Terfenadine Drug Info Allergy [ICD-11: 4A8Z] Withdrawn [4]
Trans-flupentixol Drug Info Schizophrenia [ICD-11: 6A20] Withdrawn [4]
Ximelagatran Drug Info Discovery agent [ICD-11: N.A.] Withdrawn [2]
Flesinoxan Drug Info Anxiety disorder [ICD-11: 6B00] Discontinued in Phase 3 [190]
Valspodar Drug Info Acute myeloid leukemia [ICD-11: 2A60] Discontinued in Phase 3 [4]
Apafant Drug Info Conjunctivitis [ICD-11: 9A60] Discontinued in Phase 2 [191]
Dexniguldipine Drug Info Cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 [66]
Droloxifene Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Discontinued in Phase 2 [2]
Hydroxybupropion Drug Info Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 [33]
S9788 Drug Info Cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 [2]
Tolafentrine Drug Info Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 [56]
Pafenolol Drug Info Hypertension [ICD-11: BA00] Discontinued in Phase 1 [2]
Rhodamine 123 Drug Info Prostate cancer [ICD-11: 2C82] Discontinued in Phase 1 [58]
Abamectin B1A Drug Info Parasitic worm infestations [ICD-11: 1F90] Preclinical [192]
AG1478 Drug Info Nasopharyngeal carcinoma [ICD-11: 2B6B] Preclinical [193]
BMS-3870032 Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [2]
Bouvardin Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [66]
Cephaeline Drug Info Accidental poisoning [ICD-11: PB20-PB29] Preclinical [66]
Coelenterazine Drug Info Inflammatory bowel disease [ICD-11: DD7Z] Preclinical [194]
Cycloheximide Drug Info Fungal infections [ICD-11: 1F20-1F2Z] Preclinical [13]
Desmethylsertraline Drug Info Major depressive disorder [ICD-11: 6A70.3] Preclinical [33]
E-guggulsterone Drug Info Osteoarthritis [ICD-11: FA0Z] Preclinical [195]
Epothilone A Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [2]
Geneticin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Preclinical [196]
Metildigoxin Drug Info Cardiac arrhythmias [ICD-11: BC9Z] Preclinical [32]
Metkephamid Drug Info Pain [ICD-11: MG30-MG7Z] Preclinical [66]
MG-132 Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [197]
N-desethyl sunitinib Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [198]
Nafoxidine Drug Info Advanced breast cancer [ICD-11: 2C60-2C6Z] Preclinical [45]
Nogalamycin Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [66]
Nonactin Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [52]
Okadaic acid Drug Info Alzheimer disease [ICD-11: 8A20] Preclinical [66]
Pepstatin A Drug Info Follicular lymphoma [ICD-11: 2A80] Preclinical [4]
Puromycin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Preclinical [196]
Selamectin Drug Info Infections disease [ICD-11: 1H0Z] Preclinical [192]
Silvestrol Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [199]
Bunitrolol Drug Info Discovery agent [ICD-11: N.A.] Preclinical [200]
ABT-737 Drug Info Discovery agent [ICD-11: N.A.] Terminated [177]
Calphostin C Drug Info Discovery agent [ICD-11: N.A.] Terminated [2]
Niguldipine Drug Info Discovery agent [ICD-11: N.A.] Terminated [2]
Endogenous Substrate(s) Anphiphilic compouds; Histamines; Long-chain fatty acids; Organic cations; Phospholipids; Sterols
Endogenous Metabolites (EMs) Handled by This DT Estradiol-17beta-glucuronide EM Info Identified using isolated perfused rat liver [201]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Biotin Drug Info Madin-Darby canine kidney (MDCK) cells-MDR1 Km = 13 microM [171]
Chlorpromazine Drug Info Baculovirus-infected insect cells-MDR1 Km = 27.4 microM [202]
Clozapine Drug Info Baculovirus-infected insect cells-MDR1 Km = 58 microM [202]
Colchicine Drug Info CEM/VLB100 cells-MDR1 Km = 1.33 microM [203]
Colchicine Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 1640 microM [73]
Colchicine Drug Info KB-V1 cells-overexpress MDR1 Km = 45 microM [204]
Cyclosporine Drug Info High five cells-MDR1 Km = 0.17 microM [59]
Cyclosporine Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 3.8 microM [205]
Cyclosporine Drug Info LLC-PK1 cells-MDR1 Km = 8.4 microM [206]
Daunorubicin Drug Info High five cells-MDR1 Km = 1.74 microM [59]
Dexamethasone Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 826 microM [58]
Diazepam Drug Info High five cells-MDR1 Km = 72.4 microM [59]
Digoxin Drug Info High five cells-MDR1 Km = 25.9 microM [59]
Digoxin Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 73 microM [144]
Digoxin Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 177 microM [73]
Digoxin Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 181 microM [58]
Doxorubicin Drug Info KB-V1 cells-overexpress MDR1 Km = 3 microM [204]
Etoposide Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 461 microM [73]
Etoposide Drug Info Madin-Darby canine kidney cells (MDCKII)-MDR1 Km = 255 microM [207]
Fexofenadine Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 150 microM [208]
Grepafloxacin Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 580 microM [209]
Haloperidol Drug Info Baculovirus-infected insect cells-MDR1 Km = 33 microM [202]
Indinavir Drug Info High five cells-MDR1 Km = 0.47 microM [88]
Irinotecan Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 116.1 microM [91]
Irinotecan Drug Info Madin-Darby canine kidney cells (MDCKII)-MDR1 Km = 45.5 microM [91]
Levofloxacin Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 5600 microM [209]
Levofloxacin Drug Info LLC-PK1 cells-MDR1 Km = 3000 microM [210]
Loperamide Drug Info High five cells-MDR1 Km = 13.8 microM [59]
Loperamide Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 11.4 microM [102]
Losartan Drug Info Chinese hamster ovary AA8 cells-MDR1 Km = 100 microM [181]
Losartan Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 232 microM [104]
Losartan Drug Info Madin-Darby canine kidney cells (MDCKII)-MDR1 Km = 403.2 microM [104]
Nicardipine Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 2.6 microM [58]
Olanzapine Drug Info Baculovirus-infected insect cells-MDR1 Km = 8.3 microM [202]
Oseltamivir Drug Info LLC-PK1 cells-MDR1 Km = 4.2 microM [119]
Paclitaxel Drug Info Breast carcinoma cell line (MCF7)-MDR1 Km = 0.014 microM [121]
Paclitaxel Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 16.5 microM [211]
Paclitaxel Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 65 microM [144]
Paclitaxel Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 0.7 microM [212]
Paclitaxel Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 1.4 microM [58]
Prazosin Drug Info High five cells-MDR1 Km = 20 microM [129]
Progesterone Drug Info Chinese hamster ovary AA8 cells-MDR1 Km = 30 microM [181]
Progesterone Drug Info High five cells-MDR1 Km = 53.6 microM [59]
Quetiapine Drug Info Baculovirus-infected insect cells-MDR1 Km = 12.3 microM [202]
Quinine Drug Info Chinese hamster ovary AA8 cells-MDR1 Km = 10 microM [181]
Quinine Drug Info High five cells-MDR1 Km = 5.42 microM [59]
Rhodamine 123 Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 21 microM [58]
Risperidone Drug Info Baculovirus-infected insect cells-MDR1 Km = 12.4 microM [202]
Ritonavir Drug Info LLC-PK1 cells-MDR1 Km = 0.8 microM [140]
Saquinavir Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 15.4 microM [144]
Saquinavir Drug Info LLC-PK1 cells-MDR1 Km = 14.5 microM [140]
Topotecan Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 78.3 microM [159]
Topotecan Drug Info Madin-Darby canine kidney cells (MDCKII)-MDR1 Km = 102 microM [159]
Trospium chloride Drug Info Primary human bladder urothelium cells (HBU) Km = 6.9 microM [162]
Valinomycin Drug Info Chinese hamster ovary AA8 cells-MDR1 Km = 1 microM [181]
Valinomycin Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 2.5 microM [58]
Verapamil Drug Info High five cells-MDR1 Km = 4.06 microM [59]
Verapamil Drug Info Madin-Darby canine kidney cells (MDCKII)-MDR1 Km = 24 microM [213]
Verapamil Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 2 microM [212]
Verapamil Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 4.1 microM [58]
Vinblastine Drug Info Chinese hamster ovary AA8 cells-MDR1 Km = 0.8 microM [181]
Vinblastine Drug Info High five cells-MDR1 Km = 5.71 microM [59]
Vinblastine Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 19 microM [214]
Vinblastine Drug Info Human enterocyte-like 2 cells (Caco-2)-MDR1 Km = 89.2 microM [215]
Vinblastine Drug Info LLC-PK1 cells-MDR1 Km = 99.4 microM [216]
Vinblastine Drug Info Madin-Darby canine kidney (MDCK) cells-MDR1 Km = 253 microM [215]
Vinblastine Drug Info Oocytes-MDR1 Km = 146 microM [167]
Vinblastine Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 1.7 microM [58]
Vincristine Drug Info Spodoptera frugiperda (Sf9) cells-MDR1 Km = 3.7 microM [58]
References
1 The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
2 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
3 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
6 ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 1994 Apr 25;343(2):168-72.
7 The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
8 MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44.
9 Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2015 Jan;36(1):15-33.
10 Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
11 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
12 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
13 Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
14 Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27.
15 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
16 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
17 Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.
18 Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
19 Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
20 Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol. 2017 Nov 21;23(43):7678-7692.
21 Baloxavir Marboxil FDA label
22 Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
23 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
24 P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43.
25 Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
26 Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.
27 Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
28 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
29 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
30 CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
31 In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81.
32 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
33 Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
34 Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35.
35 In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
36 Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
37 Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
38 Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8.
39 P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
40 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
41 Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality. 2010 Jul;22(7):684-92.
42 Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
43 ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86.
44 Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
45 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
46 Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
47 Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
48 Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
49 Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
50 Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
51 Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
52 Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
53 Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28.
54 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
55 Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
56 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
57 P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
58 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
59 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
60 Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62.
61 The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. Eur J Clin Pharmacol. 2008 Apr;64(4):367-72.
62 MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
63 Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.
64 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
65 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
66 Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
67 Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
68 Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24.
69 Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
70 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
71 In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
72 P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
73 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
74 Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. Ther Drug Monit. 2015 Oct;37(5):675-80.
75 Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
76 The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
77 Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73.
78 Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.
79 Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.
80 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
81 Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm. 2010 Aug 16;395(1-2):114-21.
82 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
83 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
84 Upregulation of cellular glutathione levels in human ABCB5- and murine Abcb5-transfected cells. BMC Pharmacol Toxicol. 2015 Dec 15;16:37.
85 P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Mol Pharm. 2018 Nov 5;15(11):5124-5134.
86 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
87 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
88 HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.
89 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
90 The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010 Jun 1;70(11):4509-19.
91 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
92 Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Sci Rep. 2017 Dec 13;7(1):17481.
93 MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
94 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568)
95 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
96 Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6.
97 Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75.
98 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
99 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
100 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
101 P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier inivo. Neuropharmacology. 2016 Apr;103:104-11.
102 In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75.
103 Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
104 Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
105 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
106 Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77(2):201-9.
107 Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40.
108 In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
109 Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
110 In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
111 Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
112 Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012 Apr 14;2:134-53.
113 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
114 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
115 Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541.
116 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
117 Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 May 7;12(7):871-878.
118 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12455)
119 Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61.
120 The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
121 Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
122 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
123 Invega (paliperidone) extended release tablets FDA Label
124 Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
125 Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
126 Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65.
127 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08910)
128 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
129 Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.
130 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
131 Resolor, INN-prucalopride
132 Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
133 Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
134 Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol. 2002 Aug;54(8):1055-63.
135 Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
136 Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015 Jul;32(7):2205-16.
137 Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
138 Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, initro. Pulm Pharmacol Ther. 2014 Aug;28(2):130-7.
139 Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
140 MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.
141 Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
142 Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
143 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
144 Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
145 The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43.
146 Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc. 2007 Sep;39(7):2142-4.
147 Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
148 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
149 HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci. 2001 Oct;90(10):1608-19. Comparative Study
150 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
151 JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.
152 Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes. J Pharm Pharm Sci. 2014;17(3):427-38.
153 In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319.
154 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
155 Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
156 Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
157 In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol. 2011 May;51(5):761-9.
158 The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70.
159 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
160 Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
161 Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.
162 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
163 Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68.
164 Venclexta FDA label
165 Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
166 Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
167 Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
168 L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
169 Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
170 P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002 Dec;91(12):2614-21.
171 Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol Pharm. 2006 May-Jun;3(3):329-39.
172 An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011;7:501-5.
173 Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol. 2004 Oct 6;501(1-3):151-9.
174 Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 Sep;21(9):1686-91.
175 Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
176 P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther. 2011 Jun;337(3):710-7.
177 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
178 Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16.
179 P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9.
180 P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.
181 Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.
182 Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.
183 ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6.
184 Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9.
185 Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15.
186 Unveiling the role of multidrug resistance proteins in hypertension. Hypertension. 2009 Aug;54(2):210-6.
187 Lipid dependence of ABC transporter localization and function. Chem Phys Lipids. 2009 Oct;161(2):57-64.
188 Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett. 2004 Sep 10;574(1-3):55-61.
189 Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17.
190 Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier. Eur J Pharm Sci. 2001 Aug;14(1):81-6.
191 Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci. 2002 Aug;16(3):119-28.
192 Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci. 2007 Jan;30(1):84-94.
193 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
194 Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1702-7.
195 Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun. 2008 May 2;369(2):363-8.
196 ATP-binding cassette transporters as pitfalls in selection of transgenic cells. Anal Biochem. 2010 Apr 15;399(2):246-50.
197 Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem. 2010;74(9):1913-9.
198 P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
199 Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 2011 Sep;13(3):357-64.
200 Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90.
201 MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Cancer Res. 1996 Nov 1;56(21):4992-7.
202 In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9.
203 A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7.
204 Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6.
205 Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. Clinical Trial
206 Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80.
207 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
208 Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404.
209 Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6.
210 Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60.
211 Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998 Apr;26(4):343-6.
212 Synthesis and evaluation of 3D templates based on a taxane skeleton to circumvent P-glycoprotein-associated multidrug resistance of cancer. Bioorg Med Chem Lett. 2005 May 16;15(10):2601-5.
213 Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein (P-gp/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1). J Med Chem. 2012 May 24;55(10):4683-99.
214 Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem. 1993 Jul 15;268(20):14991-7.
215 Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.
216 Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.